共 50 条
Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?
被引:12
|作者:
Demir, Lutfiye
[1
]
Ekinci, Nese
[2
]
Erten, Cigdem
[1
]
Kucukzeybek, Yuksel
[1
]
Alacacioglu, Ahmet
[1
]
Somali, Isil
[3
]
Can, Alper
[1
]
Dirican, Ahmet
[1
]
Bayoglu, Vedat
[1
]
Akyol, Murat
[1
]
Cakalagaoglu, Fulya
[2
]
Tarhan, Mustafa Oktay
[1
]
机构:
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词:
Gastrointestinal stromal tumor;
immunohistochemistry;
predictive potential;
prognosis;
IMATINIB MESYLATE;
C-KIT;
GIST;
MUTATIONS;
SURVIVAL;
RECURRENCE;
RESISTANCE;
DIAGNOSIS;
D O I:
10.7314/APJCP.2013.14.8.4751
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文